Sanofi and MD Anderson Sign a Five-Year Pact to Expedite Oncology Research and Development
Shots:
- Sanofi and MD Anderson collaborated for 5yrs. to ramp up the development of investigational treatments- including targeted and immune-therapies for oncology patients. The alliance will support investigations into additional indications and combinations for studies already in the clinic
- The collaboration will integrate MD Anderson's clinical trials infrastructure and Sanofi's pipeline of investigational treatments to lead biomarker-driven clinical studies for better understanding of novel cancer drugs mechanism
- New findings- large-scale molecular and phenotype datasets will be applied to the design of new translational studies on selected Sanofi molecules- and guide the selection of indications. The companies are expected to launch their first projects in summer 2020
Click here to read full press release/ article | Ref: Sanofi | Image: TechtrendsKE
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com